KRAS and neoplasm: iExosomes demonstrated an enhanced ability to target mutant KRAS and resulted in significant tumor reduction in vivo, attributed to CD47-dependent suppression of clearance from circulation and oncogenic KRAS-dependent enhancement of micropinocytosis [46].